Important Safety Information
GLP-1 Medications (Semaglutide & Tirzepatide)
Boxed Warning
WARNING: RISK OF THYROID C-CELL TUMORS. In rodents, semaglutide and tirzepatide cause dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide and tirzepatide are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Contraindications
Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use if you have a known hypersensitivity to semaglutide, tirzepatide, or any of the excipients.
Common Adverse Events
The most common adverse events (incidence >=5%) include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, and gastroesophageal reflux disease.
Additional Information
Tell your healthcare provider about all medical conditions, including if you have a history of pancreatitis, kidney problems, diabetic retinopathy, or depression/suicidal thoughts. Inform your provider of all medications you take, including insulin or other diabetes medications.